Will Garvin, Shareholder in the firm's FDA & Biotechnology practice, comments on the impact of the FDA's recent approval of an epilepsy drug, Epidiolex, the Administration's first approved medical use of cannabidiol in The Street's "FDA Approval of GW Pharma's Cannabis-Based Drug Marks Milestone."